ArticleLung cancer (Amsterdam, Netherlands)2020
Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
Article in Lung cancer (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis.Cancer medicine · 2021Pooled it
- SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.Cell death & disease · 2023Review
- Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.Journal of medical virology · 2023Article
- Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era.Cancers · 2021Article
- Infections and Immunotherapy in Lung Cancer: A Bad Relationship?International journal of molecular sciences · 2020Review
- Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.Journal for immunotherapy of cancer · 2020Article
- Article
- Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?Cancers · 2020Review
- The Landscape of COVID-19 in Cancer Patients: Prevalence, Impacts, and Recommendations.Cancer management and research · 2020Review
- A Nasopharyngeal Carcinoma Patient With COVID-19 Infection After Immunotherapy: A Case Report and Literature Review.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.